January 2023 | Targeted Therapies in Oncology

January 23, 2023

Although the need for novel approaches to treat patients with TP53-mutated acute myeloid leukemia remains urgent, cautious optimism may be in order given recent data from clinical trials and upcoming studies.

January 22, 2023

In a presentation delivered at the 2022 Large Urology Group Practice Association Annual Meeting, Evan Y. Yu, MD, discussed different sequencing strategies that can be utilized for patients with mCRPC and the data that support each approach.

January 21, 2023

Treatment with tisagenlecleucel in patients with relapsed/refractory B-cell acute lymphoblastic leukemia led to a 79% morphologic complete response rate.

January 20, 2023

Recent updates to clinical care for patients with ER-positive disease include the emergence of breast cancer subtypes, oral selective estrogen receptor degraders, and other oral targeted therapies.

January 19, 2023

Findings from a phase 1/2 trial showed that sotigalimab plus pembrolizumab led to antitumor activity and was well tolerated in the frontline setting of patients with metastatic melanoma.

January 18, 2023

Updated findings from the TACTI-002 trial of pembrolizumab and eftilagimod alpha in non–small cell lung cancer were presented during the Society for Immunotherapy of Cancer 37th Annual Meeting & Pre-Conference.

January 18, 2023

According to findings from the phase 1 COBALT-RCC trial, CTX130 led to an objective response rate of 8%, a stable disease rate of 69%, and a disease control rate of 77% in patients with advanced clear cell renal cell carcinoma.

January 17, 2023

Several studies with data released or presented in 2022 did not meet the threshold for significance or achieve their primary end points. Although such results are disappointing, takeaways from the trials can be used by the field as a whole to improve clinical trial design and achieve greater success in the future.

January 17, 2023

Demands by patients, market pressures, and changing delivery models have brought to the fore the urgency to address whether subspecialization is necessary and entirely feasible.

January 16, 2023

John M. Burke, MD, highlights progress in the field of hematology and oncology presented at the 64th American Society of Hematology Annual Meeting and Exposition.